Search

everythinglearnresearchcommunity

for

Search:↓

Microneedling regimens for hair loss, with users discussing needle lengths and frequencies. One user reports noticeable improvement at the crown using 1mm weekly, while another uses Keto shampoo with dermastamping.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

The post discusses using ImageJ software to objectively track hair regrowth progress. The user is treating Androgen alopecia with dutasteride and minoxidil.

Trans woman experiences hair thinning despite low testosterone and treatments like finasteride and microneedling. Possible causes discussed include past eating disorder and current stack of medications and supplements.

The user "AcanthocephalaNo7632" shared their progress with hair loss, mentioning the use of minoxidil and finasteride. Some users questioned the authenticity of the progress pictures.

Affordable 92-LED caps may be more effective for hair growth than expensive 270-laser caps due to higher power output and irradiance. The LED caps deliver more energy to the scalp, making them a cost-effective alternative for red light therapy.

RU58841 may cause heart-related side effects like palpitations and chest pain, though evidence is mostly anecdotal. Users report mixed experiences, with some stopping due to side effects and others using it without issues, but concerns about its safety and sourcing remain.

A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

An 18-year-old with Norwood 2 hair loss is considering finasteride treatment. Bloodwork shows testosterone and hormone levels mostly within normal ranges, except for low estradiol.

The conversation is about a user sharing their hair transplant results and seeking feedback. They are taking finasteride, minoxidil, oral minoxidil, vitamins, and using special shampoo to maintain their hair.

The user is experiencing thinning at the temporal points and has been using minoxidil, dermarolling, and a mixture of natural oils to improve hair growth. They are considering finasteride as a potential treatment based on shared information.

The conversation discusses using T3 (triiodothyronine) as a topical treatment for hair growth, with some users noting it showed promising results in studies but lacked follow-up. Users express interest in trying T3 due to its potential effectiveness compared to Minoxidil.

Exosome therapy for hair loss is being discussed, with mixed personal experiences and no significant results reported by some users. The treatment is expensive, and users are skeptical about its effectiveness.

The user is considering a hair transplant for frontal temple density but is concerned about shock loss. They have been using finasteride for about two years and are advised to consider minoxidil and microneedling for better results.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

The user "Expliced" shared their progress pictures after using finasteride, minoxidil, and microneedling for 1 year and 3 months. Another user mentioned that using a high-definition camera with flash and sharpening the photo can show new hairs appearing sooner.

The conversation is about microneedling for hair loss. The conclusion is that there are differing opinions on the depth and frequency of microneedling, with some studies suggesting positive results with 1.5mm depth once a week, while others prefer lower depths and less frequent sessions.

ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.

Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.

PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.

The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.

A user shared their 4-month hair transplant progress with 3740 grafts, showing before and after pictures. They had a generally good experience, except for the anesthesia part.

CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.

A user shared his experience of having two healthy children while continuously using finasteride (Fin) for hair loss, challenging fears about its potential impact on fetal development. The discussion that followed included various perspectives, with some users sharing similar experiences, others expressing concerns about potential risks, and some emphasizing the need for more substantial evidence before drawing conclusions.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.

The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.